Business & Finance
Tue, November 3, 2009Mon, November 2, 2009Sun, November 1, 2009Sat, October 31, 2009Fri, October 30, 2009Thu, October 29, 2009Wed, October 28, 2009Tue, October 27, 2009Mon, October 26, 2009Sat, October 24, 2009Fri, October 23, 2009Thu, October 22, 2009Allon CEO to Present at Bio Investor Forum and Bio Europe Conferences
Published in Business and Finance on Thursday, October 29th 2009 at 6:40 GMT by Market Wire
VANCOUVER, BRITISH COLUMBIA--(Marketwire - Oct. 29, 2009) - Allon Therapeutics Inc. (TSX:NPC) President and CEO Gordon McCauley will present an update of the Company's business progress at two upcoming investment and partnering conferences attended by public and private equity investors, research analysts, investment bankers, and the pharma community.
On October 29th, 2009 at 2:00pm PST, McCauley will address the 8th Annual BIO Investor Forum in San Francisco, sponsored by the Biotechnology Industry Organization, the world's largest organization representing the biotech industry. The forum is exploring investment trends and opportunities in life sciences, with a focus on public and venture-stage growth companies as well as those poised to join the growth "watch list" for 2010.
The presentation is being webcast live at:
[ http://www.corporate-ir.net/ireye/confLobby.zhtml?ticker=NPC.TO&item_id=2478560 ].
The presentation will be immediately archived and available for viewing for three months after the live webcast and can also be viewed from the Company's website at [ http://www.allontherapeutics.com/events_webcasts.html ].
On November 3rd, 2009 at (need to confirm PST time for presentation), McCauley will present at the 15th Annual 2009 Bio-Europe Partnering conference in Vienna, Austria. BIO-Europe is Europe's largest partnering conference, serving the global biotechnology industry. The conference annually attracts leading dealmakers from biotech, pharma and finance along with the most exciting emerging companies.
Previously on October 27th, 2009, Allon President and CEO Gordon McCauley was invited to be part of a distinguished panel at the 2009 Neurotech Leaders Forum and NeuroInvestment Conference in Newport Beach. The meeting highlighted the issues most central to the neurotherapeutics field. The conference is sponsored by Neurotech Reports, a journal serving the scientific, medical, engineering and financial communities related to neurotechnology research, products and corporate development.
About Allon's neuroprotective platforms
Allon's two neuroprotective technology platforms are based on naturally occurring proteins produced by the brain in response to a range of insults. The platforms are activity-dependent neuroprotective protein (ADNP) and activity-dependent neurotrophic factor (ADNF).
Because the two platforms are based on different proteins, the drugs from each are different molecules with different therapeutic mechanisms and distinct commercial opportunities. Clinical-stage drugs davunetide intranasal (AL-108) and davunetide intravenous (AL-208) are derived from ADNP, while preclinical stage drugs AL-209 and AL-309 are derived from ADNF. ADNP drugs davunetide intranasal (AL-108) and davunetide intravenous (AL-208) are focused on Alzheimer's disease, frontotemporal dementias, and cognitive impairment. ADNF drug candidate AL-309 is being developed for the treatment of peripheral neuropathies and is administered orally or subcutaneously.
About Allon
Allon Therapeutics Inc. is a clinical-stage biotechnology company focused on developing the first drugs that impact the progression of neurodegenerative diseases. Allon's drug davunetide has demonstrated human efficacy in amnestic mild cognitive impairment, a precursor to Alzheimer's disease, and schizophrenia-related cognitive impairment. Allon has Phase II human efficacy programs pursuing large underserved markets: Alzheimer's disease, frontotemporal dementia, and schizophrenia-related cognitive impairment. The Company is listed on the Toronto Stock Exchange under the trading symbol "NPC" (Neuro Protection Company™) and based in Vancouver. For additional information please visit the Company's website: [ www.allontherapeutics.com ].
Forward Looking Statements
Statements contained herein, other than those which are strictly statements of historical fact may include forward-looking information. Such statements will typically contain words such as "believes", "may", "plans", "will", "estimate", "continue", "anticipates", "intends", "expects", and similar expressions. While forward-looking statements represent management's outlook based on assumptions that management believes are reasonable, forward-looking statements by their nature are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by them. Such factors include, among others, the inherent uncertainty involved in scientific research and drug development, Allon's early stage of development, lack of product revenues, its additional capital requirements, the risks associated with successful completion of clinical trials and the long lead-times and high costs associated with obtaining regulatory approval to market any product which Allon may eventually develop. Other risk factors include the limited protections afforded by intellectual property rights, rapid technology and product obsolescence in a highly competitive environment and Allon's dependence on collaborative partners and contract research organizations. These factors can be reviewed in Allon's public filings at [ www.SEDAR.com ] and should be considered carefully. Readers are cautioned not to place undue reliance on such forward-looking statements and Allon disclaims any obligation to update or announce changes in any such factors except in its periodic filings.
